STOCK MARKET BSE NSE

COVID-19: Bharat Biotech gets nod for Covaxin clinical trials through skin

It also helps in reducing per-injection cost of vaccines and is also found to be more effective in inducing immune response.

Published: 24th August 2020 08:23 AM  |   Last Updated: 24th August 2020 01:05 PM   |  A+A-

'COVAXIN' was developed and manufactured at the company's Bio-safety Level-III high containment facility at Genome Valley.

'COVAXIN' was developed and manufactured at the company's Bio-safety Level-III high containment facility at Genome Valley.  (Photo| Special Arrangement)

Express News Service

HYDERABAD: Hyderabad-based vaccine manufacturer Bharat Biotech has received permission from the Central Drugs Standard Control Organisation (CDSCO) to take up clinical trials of its Covid-19 vaccine candidate, Covaxin, to be administered through the intradermal route.

While the company’s vaccine candidate is already under clinical trials at 12 centres across the country, it is being administered through the intramuscular route in which the vaccine is delivered by injection into the muscles.

Vaccine administration via the intradermal route means the vaccine will be delivered by injection into the dermis, which is the layer beneath the outer layer of skin (epidermis). According to the WHO, intradermal technique is ‘dose-sparing’, which means it consumes less vaccine than the intramuscular delivery method. It also helps in reducing the per-injection cost of vaccines and is also found to be more effective in inducing an immune response.

According to the minutes of the meeting held in New Delhi on August 13, of the Subject Expert Committee (SEC) for Covid-19 under accelerated approval process, Bharat Biotech presented its proposal for the conduct of Phase I/II clinical trials of Covaxin by intradermal (ID) route.

It also presented animal toxicity data of the vaccine candidate generated through the intradermal/intraperitoneal route along with the interim safety data from  Phase I study of the vaccine through the intramuscular route.

While the SEC recommended for grant of permission to conduct clinical trials through the intradermal route, it laid down two conditions —  the trial sites should be different from the sites where the present clinical trials are going on for the vaccine through the intramuscular route and that the subject should be followed up for six months for clinical and antibody titer assessments.

Hetero Drugs to conduct Phase IV trials  

The CDSCO also gave permission to Hyderabad- based Hetero Drugs, along with two other pharma companies, Mylan and Cipla, to conduct the Phase IV clinical trials of their version of the Covid-19 drug, Remdesivir

More from Telangana.

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

IPL_2020
flipboard facebook twitter whatsapp